Statement re Investment

Eurovestech PLC
5 March 2002



                                                           For Immediate Release

                                                                 5th March, 2002


                        EUROVESTECH PLC ('Eurovestech')

                            Statement re Investment

D-Pharm achieves first milestone payment from Shire Pharmaceuticals, pursuant to
          Phase II clinical trial for is anti-epileptic agent SPD 421


Eurovestech is pleased to report that one of its investee companies, D-Pharm Ltd
('D-Pharm'), has achieved its first milestone payment pursuant to the Phase II
clinical trial progress of SPD 421 as add-on therapy in the treatment of complex
partial seizures. SPD 421 is a drug widely used for the treatment of epilepsy,
bipolar disorder and migraine prophylaxis.



D-Pharm already has R&D collaborations with Nycomed Amersham Imaging and with
Eli Lilly & Company.



The milestone payment follows a worldwide development and commercialisation
agreement between D-Pharm and Shire Pharmaceuticals Group plc made in March 2000
and follows an initial $2 million payment received at that time. Upon the
achievement of milestones specified in the agreement, D-Pharm shall receive
additional payments that may amount to approximately $50 million. D-Pharm is
also entitled to royalty payments derived from future sales of the product.



The worldwide market for anti-epileptics in 1999 was valued at over $3.0 billion
and is projected to grow to $4.5 billion by 2005. Yet, the market is still
largely under-served, with about 20-25% of epilepsy patients still resistant to
current anti-epileptic drug treatments. SPD 421 was developed to safely serve
the needs of this patient population. Moreover, by reducing doses and side
effects it may be possible to expand the use of this important therapeutic agent
in additional indications.



Dr. Alex Kozak, D-Pharm's President and CEO, said ' The use of SPD 421 in
patients is a tremendously exciting event for D-Pharm. We are looking forward to
seeing our efforts finally benefit patients.'



Commenting on the investment in D-Pharm, Richard Bernstein, Chief Executive of
Eurovestech said: ' The milestone payment to D-Pharm represents a significant
achievement in the progress towards substantial revenues.'



Enquiries:



Eurovestech plc
Richard Bernstein - Chief Executive                Tel [phone]
[e-mail]



                      This information is provided by RNS
            The company news service from the London Stock Exchange